Clean air for Pharmaxis
13 August, 2008 by Dylan Bushell-EmblingPharmaxis concludes dose study of Bronchitol in cystic fibrosis patients
Another win for CogState
12 August, 2008 by Dylan Bushell-EmblingCogState wins $1.2 million technology contract
Acrux simplifies KV deal
12 August, 2008 by Dylan Bushell-EmblingAcrux expands partnership agreement with KV Pharmaceuticals
Knees next for Mesoblast
12 August, 2008 by Dylan Bushell-EmblingMesoblast's stem cells able to regenerate damaged knee cartilage
Growth for Tissue Therapies
11 August, 2008 by Kate McDonaldTissue Therapies begins first trial in patient with venous ulcer
Biota targets the sniffles
11 August, 2008 by Kate McDonaldBiota begins dosing in early stage cold preventative
Virax gets green light in Africa
08 August, 2008 by Kate McDonaldVirax gets approval for early phase trial of HIV vaccine in South Africa
Hexima scores with DuPont
07 August, 2008 by Dylan Bushell-EmblingHexima to partner with DuPont for new fungal resistance technology
Pharma and academia - how opposites attract
07 August, 2008 by Kate McDonaldThey may have sneered at each other in the past, but collaborative efforts for translational research between academia and industry are happening, and they are working.
Patent on the destination
07 August, 2008 by Kate McDonaldAustralian medical device company Ventracor is so pleased with its clinical trial design, it's decided to apply for a patent for it.
CRX08: Who's who of clinical research
06 August, 2008 by Fiona WylieFresh from his role as one of the head spruikers of Queensland biotech at BIO in San Diego and DIA in Boston, the CEO of the Queensland Clinical Trials Network, Mario Pennisi, is looking forward to hosting CRX08.
Bone union for Mesoblast
06 August, 2008 by Dylan Bushell-EmblingPatients achieve bone union in long-time non-healing bones after implantation of Mesoblast's adult stem cells
Ciba turns down Biosignal compounds
06 August, 2008 by Dylan Bushell-EmblingBad news for Biosignal on Ciba evaluation agreement
ResMed reports stellar result
06 August, 2008 by Dylan Bushell-EmblingResMed's share price soars following impressive fourth-quarter and financial year earnings figures.
